Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience

Affiliations

¹ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy.
² Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy; Pediatric Oncohematology, Stem Cell Transplantation and Cell Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
³ Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy.
⁴ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy.
⁵ Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy; Division of Hematology, Allogeneic Transplant and Cell Therapy Unit, AOU "Città della Salute e della Scienza di Torino" University of Turin, Italy.
⁶ Division of Hematology, Allogeneic Transplant and Cell Therapy Unit, AOU "Città della Salute e della Scienza di Torino" University of Turin, Italy.
⁷ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy. Electronic address: cerranomarco@gmail.com.

Multicenter Study

Irene Urbino et al. Leuk Res. 2024 Jan.

. 2024 Jan:136:107421.

doi: 10.1016/j.leukres.2023.107421. Epub 2023 Nov 18.

¹ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy.
² Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy; Pediatric Oncohematology, Stem Cell Transplantation and Cell Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
³ Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy.
⁴ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy.
⁵ Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy; Division of Hematology, Allogeneic Transplant and Cell Therapy Unit, AOU "Città della Salute e della Scienza di Torino" University of Turin, Italy.
⁶ Division of Hematology, Allogeneic Transplant and Cell Therapy Unit, AOU "Città della Salute e della Scienza di Torino" University of Turin, Italy.
⁷ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy. Electronic address: cerranomarco@gmail.com.

No abstract available

Keywords: Acute myeloid leukemia; Chemotherapy; FLT3; Relapsed/refractory; Sorafenib.

Conflict of interest statement

Declaration of Competing Interest None.